Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

MATINS Update

Faron Pharmaceuticals Oy (“Faron” or the “Company”) ·Safety and efficacy results from Part I of MATINS study presented in poster at ASCO20 Virtual · Patient recruitment for Part II in multiple cohorts progressing well    Company announcement, 01 June 2020 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces that the safety and efficacy results from Part I of the MATINS trial have been presented in a poster at the virtual ASCO20 (American Society of

Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

1 June 2020 07:00 BST Brilinta approved in the US to reduce the risk of a first heartattack or stroke in high-risk patients with coronary artery disease New Brilinta indication expands treatment to high-riskcoronary patients without a history of stroke or heart attack AstraZeneca's Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease. The approval by the US Food and Drug Administration (FDA) was based on positive results from the

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

1 June 2020 07:00 BST Lynparza recommended for approval in EU by CHMP forBRCA-mutated metastatic pancreatic cancer Only PARP inhibitor to demonstrate patient benefit in a Phase III trial in this setting AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for

New CEO starts at Resurs - Nils Carlsson is focused on continued growth, data-driven innovation and customer experience

From 1 June, Nils Carlsson will be the new President of Resurs Bank and CEO of Resurs Holding. Nils Carlsson has a wealth of international experience from industries experiencing change such as fintech, e-commerce and telecommunication, and most recently served as CEO of Fortnox. His initial focus will be on guiding Resurs through the prevailing global circumstances in a stable manner. At the same time, Nils Carlsson has his sights set on continued growth, data-driven innovation and customer experience.Resurs is the Nordic countries’ leading niche bank with extensive experience of

New CEO starts at Resurs - Nils Carlsson is focused on continued growth, data-driven innovation and customer experience

From 1 June, Nils Carlsson will be the new President of Resurs Bank and CEO of Resurs Holding. Nils Carlsson has a wealth of international experience from industries experiencing change such as fintech, e-commerce and telecommunication, and most recently served as CEO of Fortnox. His initial focus will be on guiding Resurs through the prevailing global circumstances in a stable manner. At the same time, Nils Carlsson has his sights set on continued growth, data-driven innovation and customer experience.Resurs is the Nordic countries’ leading niche bank with extensive experience of

Azelio business update - Continued progress and increased capital requirements due to Covid-19

Azelio has previously announced that Covid-19 will postpone the company's overall time plan by one quarter because of existing travel restrictions. At the same time, investments related to the start of production have been moved forward, which is why the company is now financed until December 2020 (earlier September 2020). Three months' delay is also expected to be valid until Azelio reaches positive cashflow, leading to an increased funding need of approximately SEK 75 million. Concretization of the increased need has emerged after evaluating the project's impact from the postponed time

New analysis confirms that multiple myeloma patients in the OCEAN study stay on treatment longer than previously estimated - results expected H1-2021

STOCKHOLM — June 1, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a consequence, top-line results are estimated for H1 2021 instead of previously communicated Q4 2020. Patient recruitment in OCEAN will remain open to ensure that the 339 disease progression events needed to complete the study can be reached within a reasonable timeframe.OCEAN is a randomized, comparative study between melflufen and pomalidomide in patients with relapsed refractory multiple myeloma (RRMM). The patients enrolled

Agreement extended with CEO Magnus René

The Board of Directors of Ovzon and Magnus René have extended the CEO appointment for Magnus René until the end of 2021.Magnus René is, since May 2018, a director of Ovzon and was appointed as the CEO in May 2019 for the period up to October 2020. Magnus René will now continue the work started to help accelerate the industrialization of Ovzon’s offering as well as optimizing the organization in support of the business plan. FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser. For further information please contact: Anders BjörkmanChairman of the

Elekta Nomination Committee’s proposed Board of Directors for the 2020 Annual General Meeting

STOCKHOLM, June 1, 2020 – The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2020 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Secher, Birgitta Stymne Göransson and Cecilia Wikström. Tomas Puusepp has declined re-election. The Nomination Committee’s complete proposal will be published in the notice of Elekta's Annual General Meeting 2020, to be held on August 26, 2020. The Nomination Committee, prior to the 2020 Annual General

Polygiene Stays Fresh Technology now available with Royal Enfield’s new range of apparel

Polygiene, the global leader in Stays Fresh Technologies has partnered with Royal Enfield Apparel to create a new range including helmets, t-shirts, balaclavas, neck- and headgear, riding jackets and gloves, etc.   A number of items including headgears will be launched with a combination of Polygiene® Biostatic and Odor crunch stays fresh technologies, that stops the growth of odor causing bacteria and makes products feel fresh and clean in all conditions and environments. More products will be added in the coming seasons, both from the protective and lifestyle lines. The

European Lingerie Group AB publishes unaudited First Quarter 2020 Report and reports continued breach of maintenance test under the bond terms and conditions

European Lingerie Group AB (“ELG” or the “Group“) publishes unaudited First Quarter 2020 Report (1 January – 31 March 2020), including condensed interim consolidated financial statements and reports a financial covenant breach under the terms and conditions for its bond (the “Bond Terms and Conditions”) for the reference period ending on 31 March 2020.“We are all facing a dynamic and unprecedented situation due to the COVID-19 outbreak, which started in Wuhan, China and in the first quarter of 2020 affected practically the whole world. The imposed restrictions by the governments had a

Restructuring Implementation Agreement - update

Reference is made to the stock exchange notice 8 May 2020 where Solstad Offshore ASA (the "Company") and its subsidiaries ("SOFF" or the "Group") informed that it had agreed a Restructuring Implementation Agreement (the "RIA") for a restructuring of the Group (the "Restructuring"). Reference is also made to the stock exchange notice earlier today in which it was advised that the bondholders in the Group have voted in favour of the Restructuring. The Company is pleased to announce that credit committee approvals have been provided by a vast majority of the secured lenders participating

Lundin Gold Share Capital and Voting Rights Update

VANCOUVER, BC, May 29, 2020 /CNW/ - Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) reports the following in accordance with the Swedish Financial Instruments Trading Act.  The Company has 225,092,583 common shares issued and outstanding with voting rights as at May 29, 2020. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the Swedish Financial Instruments Trading Act on disclosure of major

SEMAFO Obtains Court Approval of the Arrangement with Endeavour

This is information that SEMAFO Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 17:00 Eastern time on May 29, 2020.Montreal, Quebec, May 29, 2020 /CNW/ – SEMAFO Inc. (TSX, OMX: SMF) (“SEMAFO”) is pleased to announce that the Superior Court of Québec today issued a final order approving the previously announced Plan of Arrangement pursuant to which SEMAFO will combine with Endeavour Mining Corporation (the “Arrangement”). The parties have now satisfied all

Josemaria Share Capital and Voting Rights Update

VANCOUVER, May 29, 2020 /CNW/: Josemaria Resources Inc. (TSX: JOSE) (OMX: JOSE) (“Josemaria Resources” or the “Company”) reports that, in accordance with the Swedish Financial Instruments Trading Act, as a result of the issuance of common shares pursuant to the terms of previously announced credit facilities, the number of issued and outstanding shares of the Company has increased to 251,967,816 common shares with voting rights as at May 29, 2020. ADDITIONAL INFORMATIONThis information is information that the Company is obliged to make public pursuant to the Swedish Financial

Lundin Mining Announces Updated Share Capital and Voting Rights

Toronto, ON, May 29, 2020 /CNW/ - (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) reports the following updated share capital and voting rights, in accordance with the Swedish Financial Instruments Trading Act: As a result of the exercise of employee stock options or the vesting of employee share units from May 1, 2020 to date, the number of issued and outstanding shares of the Company has increased to 733,632,947 common shares with voting rights as at May 29, 2020. The information in this release is subject to the disclosure

Dome Energy AB presents the annual report for 2019

Dome Energy AB.  (herein after “Dome” and/or “the Company”) is pleased to announce that the audited annual report has been published on the Company’s website. The report is available at the website of Dome Energy (publ) https://www.domeenergy.com/financial-reports/annual-reports/ and enclosed in this press release.   For further information, please contact: Pål Mørch, CEOPhone: +1 713 385 4104E-mail: pm@domeenergy.comAbout Dome EnergyDome Energy AB. is an independent Oil & Gas Company publicly traded on the Nasdaq First North exchange in

Dome Energy hereby reports a deviation in the Annual Report for 2019 compared to the previously submitted Interim report for July-December 2019 and the Annual Report for 2018

Dome Energy AB.  (herein after “Dome” and/or “the Company”) is pleased to announce that the audited annual report has been published on the Company’s website. During February 2018, warrants were issued. The warrants were then partly incorrectly recorded as debt. In 2019, these warrants expired and the liability was dissolved over the income statement as financial income. Correct accounting principle would have been to post the warrants as equity in 2018. This has now been adjusted for in the upcoming Annual Report but represents a deviation from the

Change in the number of shares and votes in Starbreeze

STOCKHOLM, SWEDEN (29 May 2020) – Starbreeze AB today announces that the number of Class B shares increased by 2,966 and the number of Class A shares decreased by the same number during May due to the company’s ongoing conversion program. The number of votes decreased by 26,694.        In accordance with the articles of association Class A shares shall, upon request of the holder of such shares, be converted into Class B shares. In May 2,966 Class A shares were converted into Class B shares, which did not change the total number of shares but reduced the number of votes. As of 29 May

Bublar’s Otherworld Heroes™ wins Auggie Awards 2020

The world’s first location-based massively multiplayer online role-playing Swedish mobile game Otherworld Heroes™ is the Auggie Award winner 2020 in the category Best Game or Toy. The Auggie Awards, hosted by Augmented World Expo in Silicon Valley, has been the most recognized industry AR & VR awards show in the world since 2010. The Best Game or Toy category connects to solutions that enable digital interaction with the physical world or physical interaction in the virtual world. “We’re immensely proud, truly honored and incredibly happy! We started this journey with a dream to build

Change in the Board of Directors of Bioservo Technologies AB

Karin Ruiz has asked to resign from the Board. We thank Karin for her valuable contributions with their expertise and experience from both multinationals and smaller growth companies. She has shown great commitment to the company during the three years she has been a board member. The Board is of the opinion that the Board's current composition after the resignation still meets the company's current needs, in terms of number of members, independence and competence. The company will therefore not initiate any immediate recruitment of additional board members. For more information,

Publication of memorandum

Initiator Pharma A/S ("Initiator Pharma") hereby publishes memorandum for the company's rights issue of units, the subscription period commencing on June 2, 2020. The memorandum is available on Initiator Pharma’s (www.initiatorpharma.com) and Spotlight Stock Market’s (www. spotlightstockmarket.com) respective websites. In addition, the memorandum can be accessed via the Sedermera Fondkommission’s website (www.sedermera.se). The teaser and registration form will be published on the above-mentioned websites in connection with the start of the subscription period.Financial advisor, issuer and

Adapteo Corporation: SHARE REPURCHASE 29.5.2020

Adapteo Corporation  ANNOUNCEMENT  29.5.2020 Adapteo Corporation: SHARE REPURCHASE 29.5.2020 In the Stockholm Stock Exchange Trade date           29.5.2020Bourse trade         BuyShare                  ADAPTAmount             10 000 SharesAverage price/ share    77,9833 SEKTotal cost            779 833,00 SEK Adapteo Corporation now holds a total of 18 693 sharesincluding the shares repurchased on 29.5.2020 On behalf of Adapteo Corporation Nordea Bank Oyj

Tecnotree Corporation - Managers' Transactions - Ketkar

Person subject to the notification requirementName: Ketkar, Sanjay RamPosition: Other senior managerIssuer: Tecnotree CorporationLEI: 743700MRPVYI7ASHCX38 Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVYI7ASHCX38_20200527144735_4____________________________________________ Transaction date: 2020-05-26Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009010227Nature of the transaction: DISPOSAL   Transaction details(1): Volume: 860 Unit price: 0.1985 EUR(2): Volume: 367 Unit price: 0.199 EUR(3): Volume: 954 Unit price: 0.

There are no items matching the current filter
There are no more items matching the current filter
Back to top